Department of Legal Medicine and Bioethics, Faculty of Dentistry, "Carol Davila" University of Medicine and Pharmacy, 020021 Bucharest, Romania.
Clinical Medical Department, Faculty of Medicine and Pharmacy, Dunarea de Jos University, 47 Domneasca Street, 800008 Galati, Romania.
Medicina (Kaunas). 2024 Feb 29;60(3):418. doi: 10.3390/medicina60030418.
: Sudden cardiac death (SCD) represents a challenge to health systems globally and is met with increased frequency in the population. Over time, multiple screening methods have been proposed, including the analysis of various plasma biomarkers. This article aims to analyze for illustrative purposes the specialized literature in terms of current biomarkers and testing trends, in the case of cardiovascular diseases and implicitly sudden cardiac death. : In this regard, we searched the PubMed database from 2010 to the present time using the keywords "sudden cardiac death" and "biomarkers". The inclusion criteria were clinical trials that analyzed the effectiveness of screening methods in terms of biomarkers used in stratifying the risk of cardiac distress and/or sudden cardiac death. We excluded reviews, meta-analyses, and studies looking at the effectiveness of treatments. : An extended approach was found, through studies that brought to the forefront both classical markers analyzed by new, more performant methods, markers for other pathologies that also determined cardiovascular impact, non-specific molecules with effects on the cardiovascular system, and state-of-the-art markers, such as microRNA. Some molecules were analyzed simultaneously in certain groups of patients. : The observed current trend revealed the tendency to define the clinical-biological particularities of the person to be screened.
: 心脏性猝死 (SCD) 是全球卫生系统面临的挑战,在人群中发病率不断上升。随着时间的推移,已经提出了多种筛选方法,包括分析各种血浆生物标志物。本文旨在分析心血管疾病和心脏性猝死的当前生物标志物和检测趋势的相关专业文献。: 为此,我们使用“心脏性猝死”和“生物标志物”作为关键词,在 PubMed 数据库中检索了 2010 年至今的文献。纳入标准为分析生物标志物在分层心脏不适和/或心脏性猝死风险方面的筛选方法有效性的临床试验。我们排除了综述、荟萃分析和研究治疗效果的文献。: 通过研究发现了一种扩展的方法,这些研究突出了通过新的、更有效的方法分析的经典标志物,以及其他也会影响心血管的病症的标志物、对心血管系统有影响的非特异性分子以及最新的标志物,如 microRNA。某些分子在某些特定患者群体中同时进行分析。: 观察到的当前趋势表明,人们倾向于定义待筛选者的临床生物学特征。